
**NATIONAL ACCREDITATION BODY FOR
COLD CHAIN MANAGEMENT**
(NAB-CCM)

WHITE PAPER

**Strengthening Accountability and
Implementation in India's Pharmaceutical
Cold Chain**

Recommendations Emerging from the
2nd Cold Chain Community Meet (CC-CM), held at CDSCO Mumbai

Document Type	White Paper
Document No.	NABCCM/WP/2026/ST2, September 2026
Month of Release	September 2026

Issued by the National Accreditation Body for Cold Chain Management (NAB-CCM)

Document Information

Title	Strengthening Governance, Accountability and Implementation in India's Pharmaceutical Cold Chain
Subject	Recommendations Emerging from the 2nd Cold Chain Community Meet (CC-CM)
Document Type	White Paper
Document Number	NABCCM/WP/2026/ST2, September 2026
Issued By	National Accreditation Body for Cold Chain Management (NAB-CCM)
Month of Release	September 2026
Preceding Document	White Paper of the 1st Cold Chain Community Meet (Ref. NABCCM/WP/2026/JN1, June 2026)

Important Notice

This White Paper presents recommendations and proposals emerging from stakeholder deliberations at the **2nd Cold Chain Community Meet (CC-CM) held at CDSCO, Mumbai**. It is intended to facilitate dialogue among regulators, industry and other stakeholders and does not seek to reinterpret existing legislation.

References to regulatory provisions are indicative and remain subject to detailed regulatory and legal review. Any final requirements shall be determined by the competent regulatory authorities.

Contents

Foreword	4
Executive Summary	5
List of Abbreviations	6
1. Introduction and Background	7
1.1 Context and Rationale	7
1.2 About NAB-CCM	7
1.3 The Cold Chain Community Meet (CC-CM)	7
1.4 Purpose and Scope of this White Paper	8
2. Progress Since the 1st CC-CM	8
3. From Guidelines to Implementation	10
3.1 Design Principles for Future Guidelines	10
3.2 Proposed Mechanism	10
4. Recommendation I: Cold Chain Community (CCC) Committee and Advisory Board	11
4.1 Proposed Objective	11
4.2 Proposed Stakeholder Representation	11
4.3 Key Responsibilities	11
5. Recommendation II: Temperature-Sensitive Indicator for Cold Chain Products	12
5.1 The Concept	12
5.2 Possible Working Principle	12
5.3 Possible Nomenclature	12
5.4 Technical Evaluation Required	13
5.5 Potential Benefit	13
6. Recommendation III: End-to-End Accountability Across the Distribution Chain	14
6.1 Proposed Accountability Chain	14
6.2 Distributor Accountability	14
6.3 Transporter Accountability	15
6.4 Retailer / Receiving Point Accountability	15
7. Regulatory Alignment	15
8. Proposed Cold Chain Accountability Matrix	16
9. Proposed Implementation Roadmap	17
10. Expected Impact	17
11. Conclusion and Way Forward	18
Acknowledgements	19

Foreword

The integrity of temperature sensitive pharmaceutical products is fundamental to patient safety and public health. Maintaining the prescribed temperature conditions does not depend on a single stakeholder, it requires coordinated accountability across the entire pharmaceutical supply chain.

The 2nd Cold Chain Community Meet (CC-CM) was convened as a continuation of the stakeholder dialogue initiated through the 1st CC-CM. The meeting brought together stakeholders from the pharmaceutical and healthcare ecosystem to deliberate on practical mechanisms for strengthening cold-chain accountability and implementation.

The discussions focused, in particular, on three strategic areas:

1. Establishment of a **Cold Chain Community (CCC) Committee and Advisory Board** to develop and propose practical Cold Chain Guidelines for regulatory consideration.
2. Introduction of a **temperature-sensitive product indicator/label** to provide a simple visual indication of possible temperature exposure or excursion.
3. Establishment of **end-to-end accountability** across manufacturers, distributors, transporters and retailers to reduce the possibility of temperature excursions during distribution.

The recommendations presented in this White Paper are intended to facilitate continued dialogue among regulators, industry and other stakeholders and to support the development of practical, implementable Cold Chain and GDP frameworks in India.

Sarvesh Chaubey

Founder & Executive Chairman

National Accreditation Body for Cold Chain Management (NAB-CCM)

Executive Summary

Temperature-sensitive pharmaceutical products require controlled storage, transportation and handling throughout their distribution lifecycle. While individual organisations may have established systems for temperature monitoring and transportation, maintaining product integrity becomes significantly more challenging when the product moves across multiple entities.

The 2nd Cold Chain Community Meet (CC-CM) therefore focused on moving from general awareness towards structured accountability, regulatory guidance and practical implementation mechanisms. Three major consensus areas emerged:

Ref.	Recommendation	Summary of Proposal
I	Cold Chain Community (CCC) Committee & Advisory Board	NAB-CCM should establish a multi-stakeholder Committee and Advisory Board comprising appropriate experts and representatives from regulatory, pharmaceutical, logistics, academia and cold-chain domains. The Committee would work towards developing a practical and implementable Cold Chain Guidelines framework, which may subsequently be proposed to National Regulatory Authority (CDSCO) for its consideration.
II	Temperature-Sensitive Product Indicator	The feasibility of introducing a standardised temperature-sensitive sticker/indicator on applicable cold-chain pharmaceutical products should be evaluated. Similar to the principle of the Vaccine Vial Monitor (VVM) used for vaccines, an appropriate indicator could provide a simple visual signal regarding exposure beyond defined temperature conditions. Its technology, validation, placement, interpretation, stability and regulatory requirements would need to be evaluated before implementation.
III	End-to-End Supply Chain Accountability	Cold-chain responsibility should extend beyond the manufacturer, through a structured accountability chain: Manufacturer → Distributor → Transporter → Retailer / End User. Distributors should have defined responsibility for maintaining prescribed temperature conditions and for ensuring that appointed transporters are appropriately qualified and accountable. Appropriate receiving and storage practices should likewise be followed at the retailer/end-user level.

Taken together, this approach would help create continuous accountability across the distribution chain, rather than isolated responsibility at individual stages.

List of Abbreviations

Abbreviation	Full Form
CAPA	Corrective and Preventive Action
CC-CM	Cold Chain Community Meet
CCEI	Cold Chain Excursion Indicator (working name)
CCTI	Cold Chain Temperature Indicator (working name)
CDSCO	Central Drugs Standard Control Organization
GDP	Good Distribution Practices
GRN	Goods Receipt Note
GSDP	Good Storage and Distribution Practices
NAB-CCM	National Accreditation Body for Cold Chain Management
QA	Quality Assurance
SOP	Standard Operating Procedure
TEI	Temperature Excursion Indicator (working name)
TII	Temperature Integrity Indicator (working name)
VVM	Vaccine Vial Monitor

1. Introduction and Background

1.1 Context and Rationale

The integrity of temperature sensitive pharmaceutical products is fundamental to patient safety and public health. Such products require controlled storage, transportation and handling throughout their distribution lifecycle. Individual organisations may have established systems for temperature monitoring and transportation; however, product integrity becomes significantly more challenging to maintain once the product moves across multiple entities. Cold-chain integrity therefore cannot be secured through the efforts of a single stakeholder and requires coordinated accountability across the entire pharmaceutical supply chain.

1.2 About NAB-CCM

The National Accreditation Body for Cold Chain Management (NAB-CCM) is dedicated to strengthening excellence in cold-chain management through:

- Training
- Certification
- Accreditation
- Auditing
- Awareness
- Research
- Industry engagement
- Stakeholder collaboration
- Standardisation initiatives

NAB-CCM works towards bringing together regulators, pharmaceutical manufacturers, logistics providers, healthcare institutions, academia, technology providers and other stakeholders to strengthen India's cold-chain ecosystem. The organisation's objective is to support the development of competent professionals, robust processes and practical frameworks that improve product integrity and patient safety.

This positioning is consistent with the White Paper of the 1st CC-CM, which identified the need for regulatory improvement, manufacturer accountability, vendor qualification, competency development, and end-to-end audit and certification frameworks.

1.3 The Cold Chain Community Meet (CC-CM)

The Cold Chain Community Meet (CC-CM) is a closed-door stakeholder platform initiated by NAB-CCM to facilitate focused discussions on challenges and solutions related to pharmaceutical cold-chain management.

The 1st CC-CM established the need for stronger guidelines, training, vendor qualification, monitoring and end-to-end accountability. It also recommended that a multi-stakeholder expert committee periodically review and strengthen cold-chain guidelines and certification frameworks.

The 2nd CC-CM builds upon those discussions and focuses on converting stakeholder recommendations into structured mechanisms for implementation and regulatory consideration. It advances the earlier concept of an expert committee by proposing the establishment of a dedicated Cold Chain Community (CCC) Committee and Advisory Board.

1.4 Purpose and Scope of this White Paper

This White Paper records the recommendations emerging from the 2nd CC-CM. Its purpose is to facilitate continued dialogue among regulators, industry and other stakeholders and to support the

development of practical, implementable Cold Chain and GDP frameworks in India. It addresses three strategic areas:

1. Establishment of a Cold Chain Community (CCC) Committee and Advisory Board (Recommendation I);
2. Introduction of a temperature-sensitive product indicator (Recommendation II); and
3. Establishment of end-to-end accountability across the distribution chain (Recommendation III).

The White Paper does not seek to reinterpret existing legislation. Its recommendations are intended to serve as a basis for further consultation, technical evaluation and appropriate regulatory consideration.

2. Progress Since the 1st CC-CM

Following the recommendations emerging from the 1st CC-CM, NAB-CCM has initiated active engagement with industry and relevant stakeholders to translate those recommendations into practical initiatives. The objective has been to move beyond discussion and progressively establish an implementation-oriented Cold Chain and GDP ecosystem. The key areas of activity are summarised below.

Area of Activity	Progress
Industry & Regulatory Engagement	NAB-CCM has continued structured engagement with regulatory stakeholders, pharmaceutical manufacturers, logistics providers, academia and industry associations to discuss practical Cold Chain and GDP implementation challenges.
Cold Chain & GDP Awareness	Awareness and knowledge-sharing initiatives are being conducted for stakeholders across the pharmaceutical cold-chain ecosystem, with emphasis on practical implementation of Good Storage and Distribution Practices.
Workforce Training & Competency Development	NAB-CCM has initiated structured Cold Chain & GDP training initiatives for working professionals and other stakeholders involved in the handling, storage, transportation and distribution of temperature-sensitive products. The 1st CC-CM had specifically recommended structured awareness and competency-development programs and physical training programs across the country.
Vendor Qualification & Audit	NAB-CCM has initiated engagement with industry towards developing vendor qualification, audit and compliance-assessment mechanisms for cold-chain service providers, including logistics, transportation and warehousing partners. This directly advances the earlier recommendation for a vendor certification framework and a standardised end-to-end audit framework.
Industry Collaboration & Knowledge Platform	The Cold Chain Community (CC-CM) is being taken forward as a continuing platform for closed-door discussions, stakeholder engagement, knowledge sharing and development of practical solutions.
Guideline Development	Based on continued stakeholder discussions, NAB-CCM is progressing towards developing practical and implementable Cold Chain & GDP guidelines/frameworks, which can subsequently be placed before the appropriate regulatory authorities for consideration.

The Journey from Recommendation to Action



3. From Guidelines to Implementation

3.1 Design Principles for Future Guidelines

The 1st CC-CM identified that future guidelines should be:

- Practical
- Simplified
- Easily implementable
- Applicable across organisations of different sizes
- Relevant across the complete supply chain

It also recommended that future guidelines address storage and transportation at every level, including drivers, logistics providers, warehouse personnel, wholesalers, retailers, healthcare practitioners, caregivers and patients. The 2nd CC-CM discussions therefore focused on creating an institutional mechanism through which these requirements can be further developed.

3.2 Proposed Mechanism

The following mechanism is proposed for the development, review and implementation of Cold Chain Guidelines:



This process is intended to ensure that future guidelines are developed through technical expertise and industry consultation, while remaining subject to appropriate regulatory consideration.

4. Recommendation I: Cold Chain Community (CCC) Committee and Advisory Board

4.1 Proposed Objective

NAB-CCM should establish a dedicated Cold Chain Committee and Advisory Board to support the development and continuous review of Cold Chain Guidelines. The Committee would work towards a practical and implementable Cold Chain Guidelines framework, which may subsequently be proposed to CDSCO for regulatory consideration.

4.2 Proposed Stakeholder Representation

The Committee may include representatives and experts from the following domains:

- Pharmaceutical manufacturing
- Quality Assurance
- Regulatory affairs
- Cold-chain logistics
- Warehousing
- Distribution
- Retail pharmacy
- Hospitals
- Academia
- Packaging
- Temperature-monitoring technology
- Qualification and validation
- GDP/GSDP
- Industry associations
- Cold-chain subject matter experts

4.3 Key Responsibilities

The Committee may undertake the following responsibilities:

1. Identify current cold-chain implementation gaps.
2. Review existing guidance and industry practices.
3. Develop practical Cold Chain Guidelines.
4. Define stakeholder-wise responsibilities.
5. Develop temperature-excursion management principles.
6. Recommend monitoring and documentation requirements.
7. Develop vendor qualification principles.
8. Review implementation challenges.
9. Periodically update recommendations based on technology and industry developments.
10. Submit appropriate recommendations to CDSCO for consideration.


5. Recommendation II: Temperature-Sensitive Indicator for Cold Chain Products

5.1 The Concept

One of the key concepts discussed during the 2nd CC-CM was the possibility of introducing a temperature-sensitive visual indicator on applicable cold-chain pharmaceutical products. The proposed indicator would provide a visual signal when a product has potentially experienced temperature exposure beyond its specified conditions.

The concept is comparable, at a principle level, to the use of Vaccine Vial Monitor (VVM) technology for vaccines. However, the proposed pharmaceutical cold-chain indicator would need to be independently evaluated for different products and temperature requirements.

5.2 Possible Working Principle



5.3 Possible Nomenclature

The final terminology should be determined through technical and regulatory consultation. The following are working names only, and do not constitute final recommendations:

Working Name	Abbreviation
Cold Chain Temperature Indicator	CCTI
Temperature Excursion Indicator	TEI
Cold Chain Excursion Indicator	CCEI
Temperature Integrity Indicator	TII

5.4 Technical Evaluation Required

Before any regulatory adoption, the following parameters should be evaluated:

- Temperature range
- Exposure duration
- Product-specific requirements
- Indicator accuracy
- Stability
- Shelf life
- Irreversibility/reversibility
- Packaging compatibility
- Visual interpretation
- Validation methodology
- False-positive/false-negative risk
- Regulatory acceptance
- Cost and scalability

5.5 Potential Benefit


A standardised indicator could potentially provide an additional visual layer of product-integrity information during receiving, storage and distribution.

Note: The indicator should complement, and not replace, validated temperature monitoring, qualification and excursion-management systems.

6. Recommendation III: End-to-End Accountability Across the Distribution Chain

A central outcome of the 2nd CC-CM was the recognition that cold-chain integrity cannot be maintained by the manufacturer alone. Once the product enters the distribution network, responsibility must be appropriately distributed across all stakeholders handling the product.

6.1 Proposed Accountability Chain



This creates a connected accountability framework in which responsibility is continuous across every handover.

6.2 Distributor Accountability

Distributors occupy a critical position between manufacturers and downstream stakeholders. The proposed framework should therefore encourage distributors to:

- Use qualified transporters.
- Define temperature requirements in transporter agreements.
- Ensure appropriate temperature monitoring.
- Maintain transportation records.
- Establish excursion reporting procedures.
- Train relevant personnel.
- Ensure proper product receipt and handover.
- Maintain appropriate documentation.
- Escalate temperature excursions according to defined procedures.

The distributor should also ensure that accountability is extended to its appointed transporter.

6.3 Transporter Accountability

Transporters handling temperature-sensitive pharmaceutical products should have clearly defined responsibilities, including:

- Appropriate vehicle/equipment qualification.
- Temperature monitoring.
- Maintenance of prescribed temperature conditions.
- Defined loading/unloading procedures.
- Documentation of temperature data.
- Excursion reporting.
- Corrective action.
- Personnel competency.
- Preventive maintenance.

The White Paper of the 1st CC-CM similarly recommended that manufacturers engage qualified and validated transporters, warehouses and service providers and establish monitoring, detection, reporting and escalation protocols for temperature excursions.

6.4 Retailer / Receiving Point Accountability

The cold chain does not end when the product reaches the distributor or retailer. Receiving points should establish appropriate procedures for:

- Receiving temperature-sensitive products.
- Checking shipment condition.
- Reviewing available temperature information.
- Recording receipt.
- Appropriate storage.
- Identifying and escalating suspected excursions.
- Maintaining relevant documentation.

The White Paper of the 1st CC-CM had already identified limited oversight of storage practices at retail and hospital levels as one of the key challenges in the pharmaceutical cold-chain ecosystem.

7. Regulatory Alignment

The proposed accountability framework should be examined in the context of the applicable regulatory provisions governing pharmaceutical distribution and supply. As discussed during the CC-CM, the proposed approach may be considered in relation to the applicable requirements associated with Form 19AA and Form 19BB, subject to detailed regulatory and legal review.

The purpose of this White Paper is not to reinterpret existing legislation, but to identify how practical cold-chain accountability mechanisms may be strengthened within the applicable regulatory framework. Any final requirements should be determined by the competent regulatory authorities.

8. Proposed Cold Chain Accountability Matrix

The following matrix summarizes the proposed primary responsibility of each stakeholder and the key evidence through which such responsibility may be demonstrated.

Stakeholder	Primary Responsibility	Key Evidence
Manufacturer	Define temperature requirements & controls	SOPs, specifications, agreements
Distributor	Maintain product integrity through distribution	Shipment & temperature records
Transporter	Maintain prescribed conditions during transport	Temperature data, trip records
Retailer	Proper receipt and storage	GRN, storage records
Warehouse	Controlled storage	Mapping, monitoring records
Regulatory Authority	Regulatory oversight	Applicable regulations/guidance

The final matrix should be reviewed and validated by the proposed expert committee and relevant regulatory stakeholders.

9. Proposed Implementation Roadmap

A phased approach is proposed for translating the recommendations of this White Paper into practice:

Phase	Title	Key Activities
Phase 1	Committee Formation	Formation of the NAB-CCM Cold Chain Committee and the NAB-CCM Advisory Board.
Phase 2	Guideline Development	- Stakeholder consultation - Gap assessment - Drafting - Technical review - Industry consultation
Phase 3	Regulatory Engagement	Submission of the proposed framework/guidelines to CDSCO for appropriate consideration.
Phase 4	Pilot Implementation	Pilot implementation with selected pharmaceutical manufacturers, distributors, transporters and retailers.
Phase 5	Temperature Indicator Evaluation	Technical evaluation and controlled pilot of suitable temperature-sensitive indicator technologies.
Phase 6	Training & Awareness	Structured training for manufacturers, distributors, transporters, warehouse personnel, retailers, pharmacists and QA professionals.
Phase 7	Wider Adoption	Following regulatory and stakeholder review, suitable frameworks may be scaled across the pharmaceutical cold-chain ecosystem.

10. Expected Impact

The proposed recommendations aim to contribute towards the following outcomes:

Outcome	Description
Better Product Integrity	Improved visibility and accountability throughout distribution.
Stronger Accountability	Clearly defined responsibilities at every stage.
Improved Vendor Management	Greater emphasis on qualification and monitoring of logistics and distribution partners.
Faster Excursion Identification	Additional visual indicators may support early identification of potential temperature exposure.
Better Workforce Competency	Training and competency development across the supply chain.
Stronger GDP Implementation	Movement from general guidance towards practical implementation.

Outcome	Description
Regulatory-Industry Collaboration	A structured platform for continued dialogue between regulators and industry.

11. Conclusion and Way Forward

The 2nd Cold Chain Community Meet marks an important progression from identifying cold-chain challenges towards developing practical mechanisms for accountability, guideline development and implementation.

The establishment of a dedicated Cold Chain Community (CCC) Committee and Advisory Board can provide a structured mechanism for technical consultation and for the development of practical Cold Chain Guidelines for consideration by the competent regulatory authorities. The proposed temperature-sensitive indicator represents an opportunity to explore an additional layer of product-integrity visibility, subject to appropriate scientific, technical and regulatory evaluation.

Most importantly, maintaining cold-chain integrity requires a shared responsibility model:

Manufacturer → Distributor → Transporter → Retailer

Every handover represents a point at which temperature integrity must be maintained, documented and accountable.

NAB-CCM remains committed to facilitating continued stakeholder dialogue, capacity building, technical development and regulatory engagement towards strengthening India's pharmaceutical cold-chain ecosystem. The recommendations contained in this White Paper are intended to serve as a basis for further consultation, technical evaluation and appropriate regulatory consideration.

Acknowledgements

NAB-CCM expresses its sincere appreciation to all delegates, regulatory representatives, pharmaceutical industry leaders, logistics professionals, academicians, healthcare professionals and cold-chain experts who contributed to the 2nd Cold Chain Community Meet (CC-CM).

Their participation and insights have contributed to the continuing development of the Cold Chain Community (CCC) and to the broader objective of strengthening pharmaceutical cold-chain management in India.

Issued By

National Accreditation Body for Cold Chain Management (NAB-CCM)

Particulars	Details
Document Type	White Paper
Subject	Recommendations Emerging from the 2nd Cold Chain Community Meet (CC-CM)
Date of Release	September 2026